Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPA | P38571 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26563226 | 0.86 | LIPA (0.42) | LIPA | |
| SCHEMBL26563243 | 0.82 | LIPA (0.55) | LIPACDC25BCNR2EPHX1THRA | |
| SCHEMBL17813 | 0.82 | — | — | |
| SCHEMBL27048536 | 0.75 | — | — | |
| SCHEMBL12654754 | 0.75 | HTT (0.30) | — | |
| SCHEMBL9390306 | 0.75 | LIPA (0.47) | LIPACDC25BCNR2EPHX1HSD11B1 | |
| SCHEMBL19039736 | 0.75 | LIPA (0.47) | LIPACDC25BCNR2EPHX1HSD11B1 | |
| SCHEMBL17388557 | 0.74 | — | — | |
| SCHEMBL14646599 | 0.73 | THRA (0.39) | LIPATHRATHRB | |
| SCHEMBL25587233 | 0.73 | THRA (0.39) | LIPATHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024017977-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-01-25 | — | — | WO | disclosed |
| US-20230337523-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230337523-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, OCIAD1, OCIAD2 | LIPA 1598/4885CDC25B 3479/4885CNR2 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.